3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Leukemia, Biphenotypic, Acute
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
16
Radiotherapy
15
Drug Therapy
14
Paclitaxel
13
Cisplatin
12
Carboplatin
10
Immunotherapy
9
Esophagectomy
9
Radiation
8
Fluorouracil
8
Surgical Procedures, Operative
7
Capecitabine
7
Blood Specimen Collection
7
Oxaliplatin
6
Nivolumab
6
Immune Checkpoint Inhibitors
6
Chemoradiotherapy
6
nimotuzumab
5
Trastuzumab
5
130-nm albumin-bound paclitaxel
5
sintilimab
4
camrelizumab
4
Leucovorin
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surveys and Questionnaires
3
Endoscopy
3
Bevacizumab
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Neoplasms
×
Levoleucovorin
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled